Growth Clinical Trials

135 recruitingLast updated: May 13, 2026

There are 135 actively recruiting growth clinical trials across 45 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Los Angeles, California, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Growth Trials at a Glance

135 actively recruiting trials for growth are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Not Applicable with 27 trials, with the heaviest enrollment activity in Boston, Los Angeles, and Dallas. Lead sponsors running growth studies include Aga Khan University, Ascendis Pharma Endocrinology Division A/S, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Growth Clinical Trials

Looking for clinical trials for Growth? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Growth trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Growth clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 135 trials

Recruiting

Study of Proteus Syndrome and Related Congenital Disorders

Proteus SyndromePIK3CA Related Overgrowth Spectrum
National Human Genome Research Institute (NHGRI)1,500 enrolled1 locationNCT00001403
Recruiting
Phase 2

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Adult Growth Hormone DeficiencyGulf War Syndrome
Baylor College of Medicine20 enrolled2 locationsNCT05355272
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting

A Survey on Growth Development in Children After Liver Transplantation

Growth, Development in Pediatric Liver Transplant Recipients
RenJi Hospital275 enrolled1 locationNCT07574398
Recruiting
Phase 2

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Small Intestine Bacterial Overgrowth
University of Virginia60 enrolled1 locationNCT07451171
Recruiting
Phase 3

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Growth Hormone Deficiency (GHD)
Lumos Pharma150 enrolled28 locationsNCT06948214
Recruiting
Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled31 locationsNCT06789913
Recruiting

Autophagy/Apoptosis Balance in Placental Vascular Pathologies

Pregnancy ComplicationsPre-EclampsiaGrowth Retardation, Intrauterine
Centre Hospitalier Universitaire de Nīmes50 enrolled1 locationNCT06779916
Recruiting
Phase 2

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

PI3K Gene MutationKRAS G12DVascular Anomalies+15 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 2

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled30 locationsNCT06997588
Recruiting
Phase 1

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Phase 1Clear Cell CarcinomaGrowth Factor
M.D. Anderson Cancer Center30 enrolled1 locationNCT07072234
Recruiting

Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.

Isolated Non-acquired Growth Hormone Deficiency
Assistance Publique - Hôpitaux de Paris200 enrolled1 locationNCT07333521
Recruiting

Evaluation of Children With Endocrine and Metabolic-Related Conditions

Metabolic DiseaseAdrenal InsufficiencyBone Diseases, Metabolic+2 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)15,000 enrolled1 locationNCT02769975
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S900 enrolled27 locationsNCT05820672
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting

The Combined First Trimester Screening

Fetal Growth RestrictionPreterm LaborPreeclampsia (PE)+4 more
Institute of Health Information and Statistics of the Czech Republic2,000 enrolled3 locationsNCT07015203
Recruiting
Phase 1

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

SafetyTolerabilityAdult Growth Hormone Deficiency
Changchun GeneScience Pharmaceutical Co., Ltd.64 enrolled1 locationNCT07016802
Recruiting
Phase 3

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

Mild Traumatic Brain InjuryAdult Growth Hormone Deficiency
VA Office of Research and Development172 enrolled4 locationsNCT04867317